Aquestive Therapeutics (AQST)

• Market cap: $277M
• 1 day: -2.44%
• 5 days: 6.46%
• 1 month: -7.28%
• 3 months: -10.83%
• 6 months: -49.00%
• Year to date: -23.71%
• 1 year: -25.13%
• 5 years: -35.63%
• 10 years: -82.55%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Employees: 142

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

212% more call options, than puts

Call options by funds: $1.89M | Put options by funds: $605K

36% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 33

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

3% less funds holding

Funds holding: 117 [Q3] → 114 (-3) [Q4]

3.79% less ownership

Funds ownership: 51.37% [Q3] → 47.57% (-3.79%) [Q4]

33% less capital invested

Capital invested by funds: $232M [Q3] → $155M (-$77.8M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8 186% upside
• Avg. target: $9 221% upside
• High target: $10 257% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 36% 1-year accuracy 117 / 329 met price target	257% upside $10	Buy Reiterated	2 Apr 2025
Lake Street Thomas Flaten 50% 1-year accuracy 5 / 10 met price target	186% upside $8	Buy Maintained	7 Mar 2025